Article By:
ChinaBio® Today
Saturday, October 21, 2023 1:39 PM EDT
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin platform to Almirall in a $210 million agreement.
